VC: Aldagen gains $17.3M in third round



Aldagen gains $17.3M in third round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Aldagen
Durham, NC

$17.3M
Third

Harbert Venture Partners and Intersouth Partners

The company will use these funds to advance its pipeline of regenerative medicine clinical studies.

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.